Pharmaceutical administration form for peptides, process for its preparation, and use
A method for preventing aggregation of an LHRH antagonist in a pharmaceutical composition. The method comprises combining the LHRH antagonist in the form of an acetate, gluconate, glucuronate, lactate, citrate, ascorbate, benzoate or phosphate salt and at least one of the acids for forming the salts in free acid form.
1. A method for suppressing aggregation of the LHRH antagonist salt cetrorelix acetate in a pharmaceutical composition for parenteral administration, comprising the steps of:
providing a pharmaceutically effective amount of cetrorelix acetate, in a concentration of 2.5 mg/ml total solution;
dissolving or dispersing cetrorelix acetate in a carrier; and
including in said carrier a pharmaceutically acceptable acid and % in total solution thereof, selected from the group consisting of gluconic acid of at least 0.0071%, or glucaric acid or galacturonic acid of 2.5%, wherein the pharmaceutically acceptable acid is present as free acid and is in an amount capable of imparting a pH of 2.5 to 4.5 to the composition and suppressing aggregation of cetrorelix acetate.
2. The method of claim 1 , wherein said carrier is water, physiologically tolerable oil, or an aqueous solvent mixture.
3. The method of claim 1 , further comprising adding an excipient.
4. The method of claim 3 , wherein said excipient is selected from the group consisting of gluconic acid, glucuronic acid, galacturonic acid, glucaric acid, citric acid, ascorbic acid, an amino acid, polyethylene glycol 12-(hydroxy)stearate, polyoxyethylene ricinolcate, polysorbates, poloxamers, phospholipids, lecithins, a preservative, albumins, polyethylene glycols, cellulose derivatives, starch derivatives, polyvinylpyrrolidone, cyclodextrins or its derivatives, sugar alcohols, urea, chaotropic substances, and mixtures thereof.
5. The method of claim 1 , further comprising incorporating a polymer to delay the release of cetrorelix acetate.
6. The method of claim 5 , wherein said polymer is a homo- or copolymer of lactic or glycolic acid.
7. The method of claim 2 , wherein said oil is a medium-chain triglyceride oil, castor oil, sesame oil, cottonseed oil, maize oil, peanut oil, olive oil, or mixtures thereof.
8. The method of claim 1 , wherein said pharmaceutical composition is an injection preparation.
9. The method of claim 1 , wherein said carrier is water and wherein said pharmaceutically acceptable acid is independently selected from glucaric acid or galacturonic acid.
10. A method for preparing a pharmaceutical composition for parenteral administration, comprising a pharmaceutically effective amount of the LHRH antagonist salt cetrorelix acetate dissolved or dispersed in a carrier, comprising:
providing a pharmaceutically effective amount of cetrorelix acetate, in a concentration of 2.5 mg/ml total solution;
subjecting cetrorelix acetate to double decomposition with a pharmaceutically acceptable acid and % in total solution thereof, selected from the group consisting of gluconic acid of at least 0.0071%, or glucaric acid or galacturonic acid of 2.5%, wherein the pharmaceutically acceptable acid is present as free acid and is in an amount capable of imparting a pH of 2.5 to 4.5 to the composition and suppressing aggregation of cetrorelix acetate, to produce a corresponding cetrorelix acetate in a stoichiometric ratio;
dissolving cetrorelix acetate in water to form a solution;
sterile-filtering said solution to form a sterile-filtered solution;
dispensing said sterile-filtered solution into at least one vial;
lyophilizing said sterile-filtered material in said at least one vial to form a lyophilisate; and
reconstituting said lyophilisate with a carrier before the parenteral administration.
11. The method of claim 10 , wherein said carrier is water, physiologically tolerable oil, or an aqueous solvent mixture.
12. The method of claim 10 , further comprising adding an excipient.
13. The method of claim 12 , wherein said excipient is selected from the group consisting of gluconic acid, glucuronic acid, galacturonic acid, glucaric acid, citric acid, ascorbic acid, an amino acid, polyethylene glycol 12-(hydroxy)stearate, polyoxyethylene ricinolcate, polysorbates, poloxamers, phospholipids, lecithins, a preservative, albumins, polyethylene glycols, cellulose derivatives, starch derivatives, polyvinylpyrrolidone, cyclodextrins or its derivatives, sugar alcohols, urea, chaotropic substances, and mixtures thereof.
14. The method of claim 10 , further comprising incorporating a polymer to delay the release of said LHRH antagonist.
15. The method of claim 14 , wherein said polymer is a homo- or copolymer of lactic or glycolic acid.
16. The method of claim 11 , wherein said oil is a medium-chain triglyceride oil, castor oil, sesame oil, cottonseed oil, maize oil, peanut oil, olive oil, or mixtures thereof.
17. The method of claim 10 , wherein said pharmaceutically acceptable acid is independently selected from glucaric acid or galacturonic acid.
18. The method of claim 10 , wherein said vial is an injection vial.